1. Chambers TJ, Hahn CS, Galler R, Rice CM. Flavivirus genome organization, expression, and replication. Annu Rev Microbiol. 1990; 44:649–688.
Article
2. Erlanger TE, Weiss S, Keiser J, Utzinger J, Wiedenmayer K. Past, present, and future of Japanese encephalitis. Emerg Infect Dis. 2009; 15:1–7.
Article
3. Endy TP, Nisalak A. Japanese encephalitis virus: ecology and epidemiology. Curr Top Microbiol Immunol. 2002; 267:11–48.
Article
4. Halstead SB, Jacobson J, Dubischar-Kastner K. Japanese encephalitis vaccines. In : Plotkin SA, Orenstein WA, Offit PA, editors. Vaccines. 6th ed. Philadelphia: Elsevier Saunders Co;2013. p. 312–351.
5. Department of Health. Japanese encephalitis. In : Salisbury D, Ramsay M, Noakes K, editors. Immunisation against infectious disease. 3rd ed. London: TSO Co;2013. p. 201–208.
6. Hong YJ. The Japanese encephalitis vaccine: worldwide and korean status. Korean J Pediatr Infect Dis. 2008; 15:108–114.
Article
7. Sohn YM. The background and changes of inactivated Japanese encephalitis vaccine schedule. Korean J Pediatr Infect Dis. 2000; 7:56–70.
8. Calisher CH, Monath TP. Togaviridae and Flaviviridae: the alphaviruses and Flaviviruses. In : Lennette EH, Halonen P, Murphy FA, editors. Laboratory diagnosis of infectious diseases. 2nd ed. New York: Springer-Verlag;1988. p. 414–434.
9. Korea Center for Disease Control and Prevention. Japanese encephalitis in Korea since 2001. Public Health Wkly Rep. 2008; 1:289–292.
11. Hsu TC, Chow LP, Wei HY, Chen CL, Hsu ST. A completed field trial for an evaluation of the effectiveness of mouse-brain Japanese encephalitis vaccine. In : Hammon WMcD, Kitaoka M, Downs WG, editors. Immunization for Japanese Encephalitis. Amsterdam: Excerpta Medica;1972. p. 285–291.
12. Hoke CH, Nisalak A, Sangawhipa N, Jatanasen S, Laorakapongse T, Innis BL, et al. Protection against Japanese encephalitis by inactivated vaccines. N Engl J Med. 1988; 319:608–614.
Article
13. Yang SE, Pan MJ, Tseng HF, Liau MY. The efficacy of mouse-brain inactivated Nakayama strain Japanese encephalitis vaccine-results from 30 years experience in Taiwan. Vaccine. 2006; 24:2669–2673.
Article
14. Poland JD, Cropp CB, Craven RB, Monath TP. Evaluation of the potency and safety of inactivated Japanese encephalitis vaccine in US inhabitants. J Infect Dis. 1990; 161:878–882.
Article
15. Sohn YM, Pyun BY, Lee HJ, Kang JH, Hong YJ, Oh SH, et al. Report of study result regarding effective level of antibody persistence rate after Japanese B encephalitis vaccination. Korean J Pediatr. 1995; 38:730–731.
16. Oya A. Japanese encephalitis vaccine. Acta Paediatr Jpn. 1988; 30:175–184.
Article
17. Aihara H, Takasaki T, Matsutani T, Suzuki R, Kurane I. Establishment and characterization of Japanese encephalitis virus-specific, human CD4(+) T-cell clones: flavivirus cross-reactivity, protein recognition, and cytotoxic activity. J Virol. 1998; 72:8032–8036.
Article
18. Van der Vliet D, Simon de Fanti A, Murri S, Lapidus N, Goujon C, Zeller H, et al. Long-term seroprotection against Japanese encephalitis using an inactivated vaccine (Jevax). Med Trop (Mars). 2010; 70:155–157.
19. Ku CC, King CC, Lin CY, Hsu HC, Chen LY, Yueh YY, et al. Homologous and heterologous neutralization antibody responses after immunization with Japanese encephalitis vaccine among Taiwan children. J Med Virol. 1994; 44:122–131.
Article
20. Hennessy S, Liu Z, Tsai TF, Strom BL, Wan CM, Liu HL, et al. Effectiveness of live-attenuated Japanese encephalitis vaccine (SA 14-14-2): a case-control study. Lancet. 1996; 347:1583–1586.
Article
21. Sohn YM, Park MS, Rho HO, Chandler LJ, Shope RE, Tsai TF. Primary and booster immune responses to SA 14-14-2 Japanese encephalitis vaccine in Korean infants. Vaccine. 1999; 17:2259–2264.
Article